Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma

Hematology - United Kingdom
doi 10.1080/10245332.2016.1234186
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Informa UK Limited

Related search

Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2014English

Pembrolizumab Combined With Lenalidomide and Low‐dose Dexamethasone for Relapsed or Refractory Multiple Myeloma: Phase I KEYNOTE ‐023 Study

British Journal of Haematology
Hematology
2019English

Pcn73 - Budget Impact of Ixazomib in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in Russia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology
Hematology
2019English

Pcn173 - Cost-Effectiveness of New Triplet Combinations With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Lenalidomide Plus Dexamethasone Is More Effective Than Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Regardless of Prior Thalidomide Exposure

Blood
BiochemistryImmunologyCell BiologyHematology
2008English

Immortal Time Bias in Retrospective Analysis: Comment on ‘Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma’

Blood Cancer Journal
OncologyHematology
2015English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy